文献速递传染病防控与疫情报告免疫规划

疫苗衍生脊髓灰质炎病毒最新进展——全球,2016年1月至2017年6月

Update on Vaccine-Derived Polioviruses - Worldwide, January 2016-June 2017.
PubMed 文献 · MMWR Morb Mortal Wkly Rep · 2017-11-03

该报告更新了2016年1月至2017年6月全球疫苗衍生脊髓灰质炎病毒(VDPV)的监测情况。期间发现了新的循环型VDPV(cVDPV)疫情,包括刚果民主共和国2起(8例)和叙利亚1起(35例),尼日利亚检出与既往出现相关的cVDPV2,老挝2015-2016年cVDPV1疫情最后一例确诊病例发生于2016年1月。在10个国家新发现14名免疫缺陷相关VDPV(iVDPV)排泄者,英国和伊朗3名既往报告患者仍在排泄iVDPV2。10个国家在免疫正常者和环境样本中发现意义不明的VDPV(aVDPV)。

要点

  • 2016年1月至2017年6月,刚果民主共和国发现2起cVDPV疫情(8例),叙利亚发现1起(35例)。
  • 老挝2015-2016年cVDPV1疫情最后一例确诊病例发生于2016年1月。
  • 10个国家新发现14名iVDPV排泄者,英国和伊朗3名既往患者仍在排泄iVDPV2。

核心结论

  • 2016年1月至2017年6月报告了新的cVDPV疫情和iVDPV病例,消灭脊灰认证后停止所有OPV使用将消除新VDPV感染的风险。

研究设计与样本

  • 该报告更新了2016年1月至2017年6月全球VDPV监测情况的总结。

主要发现

  • 2016年1月至2017年6月,刚果民主共和国发现2起cVDPV疫情(8例),叙利亚发现1起cVDPV疫情(35例)。
  • 尼日利亚cVDPV2循环导致检出与既往出现相关的cVDPV2。
  • 老挝2015-2016年cVDPV1疫情最后一例确诊病例发生于2016年1月。
  • 10个国家新发现14名iVDPV排泄者,英国和伊朗3名既往报告患者仍在排泄iVDPV2。
  • 10个国家在免疫正常者和环境样本中发现aVDPV。

临床怎么用

  • 消灭脊灰认证后停止所有OPV使用将消除新VDPV感染的风险。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

In 1988, the World Health Assembly launched the Global Polio Eradication Initiative (GPEI) (1). Among the three wild poliovirus (WPV) serotypes, only type 1 (WPV1) has been detected since 2012. Since 2014, detection of WPV1 has been limited to three countries, with 37 cases in 2016 and 11 cases in 2017 as of September 27. The >99.99% decline worldwide in polio cases since the launch of the GPEI is attributable to the extensive use of the live, attenuated oral poliovirus vaccine (OPV) in mass vaccination campaigns and comprehensive national routine immunization programs. Despite its well-established safety record, OPV use can be associated with rare emergence of genetically divergent vaccine-derived polioviruses (VDPVs) whose genetic drift from the parental OPV strains indicates prolonged replication or circulation (2). VDPVs can also emerge among persons with primary immunodeficiencies (PIDs). Immunodeficiency-associated VDPVs (iVDPVs) can replicate for years in some persons with PIDs. In addition, circulating vaccine-derived polioviruses (cVDPVs) can emerge very rarely among immunologically normal vaccine recipients and their contacts in areas with inadequate OPV coverage and can cause outbreaks of paralytic polio. This report updates previous summaries regarding VDPVs (3). During January 2016-June 2017, new cVDPV outbreaks were identified, including two in the Democratic Republic of the Congo (DRC) (eight cases), and another in Syria (35 cases), whereas the circulation of cVDPV type 2 (cVDPV2) in Nigeria resulted in cVDPV2 detection linked to a previous emergence. The last confirmed case from the 2015-2016 cVDPV type 1 (cVDPV1) outbreak in Laos occurred in January 2016. Fourteen newly identified persons in 10 countries were found to excrete iVDPVs, and three previously reported patients in the United Kingdom and Iran (3) were still excreting type 2 iVDPV (iVDPV2) during the reporting period. Ambiguous VDPVs (aVDPVs), isolates that cannot be classified definitively, were found among immunocompetent persons and environmental samples in 10 countries. Cessation of all OPV use after certification of polio eradication will eliminate the risk for new VDPV infections.

来源:MMWR Morb Mortal Wkly Rep,查看原文。版权归原作者所有。

引用

  1. Jorba J, Diop OM, Iber J, et al. Update on Vaccine-Derived Polioviruses - Worldwide, January 2016-June 2017. MMWR Morb Mortal Wkly Rep. 2017. PMID: 29095803. doi:10.15585/mmwr.mm6643a6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。